Pfizer Nears Agreement to Buy Medivation for $14 Bilion

by Julia Samuel on  August 22, 2016 at 3:08 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Pfizer, US pharmaceutical giant is nearing a deal to buy US biotech firm Medivation, which specializes in cancer treatments, for nearly $14 billion, US media reported.
Pfizer Nears Agreement to Buy Medivation for $14 Bilion
Pfizer Nears Agreement to Buy Medivation for $14 Bilion

Bloomberg and The Wall Street Journal said the deal could be made public. The Journal, citing people familiar with the matter, said it could be an all-cash transaction.

Pfizer's offer for the San Francisco, California-based Medivation goes far beyond the company's market value of $11.1 billion. Medivation shares closed at $67.16.

By purchasing Medivation, Pfizer would add to its portfolio the drug Xtandi, a promising treatment against prostate cancer that analysts estimate will generate some $1.33 billion in annual sales by 2020.

The purchase would be Pfizer's biggest buy since it bought the medical device company Hospira last year for $17 billion.

The transaction is a snub to the French pharmaceutical group Sanofi, which earlier offered $58 a share, which Medivation rejected in July.

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Top Ten Selling Drugs 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive